NCT00000435View on ClinicalTrials.gov

dnaJ Peptide for Relieving Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 30, 1999

Study Completion Date

September 30, 2004

Conditions
Rheumatoid Arthritis
Interventions
DRUG

dnaJ peptide

dnaJP1 was taken in pill form at 25mg/day for 6 months

DRUG

None-placebo

placebo was taken in pill form at 25mg/day for 6 months

Trial Locations (8)

18840

Guthrie Clinic, Sayre

21224

Johns Hopkins University, Baltimore

55905

Mayo Clinic, Rochester

80230

Denver Arthritis Center, Denver

92868

University of California, Irvine Medical Center, Orange

94305

Stanford University, Palo Alto

98104

Virginia Mason Research Center, Seattle

85724-5093

University of Arizona Health Sciences Center, Tucson

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00000435 - dnaJ Peptide for Relieving Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter